SUZHOU, CHINA, May 2, 2024 -- MediLink Therapeutics (“MediLink”) today announced that the first patient has been successfully dosed with YL211 in a phase I study in the US. MediLink and Roche had previously entered into a worldwide collaboration and license agreement on YL211. Following the execution of this agreement, the Investigational New Drug (IND) application for YL211 has been cleared by the U.S. Food and Drug Administration (FDA), and a phase I study to assess the safety, pharmacokinetics and preliminary efficacy of YL211 in patients with advanced solid tumors has been initiated subsequently.

About YL211

YL211 is an innovative antibody-drug conjugate that specifically targets cMET, a member of the receptor tyrosine kinase (RTK) family. cMet plays critical roles in the initiation, aggressive growth and metastasis of multiple cancer types, making it an effective target for cancer treatment. YL211 has been developed by utilizing MediLink's Tumor Microenvironment Activable LINker-payload (TMALIN®) conjugated with a highly specific cMet antibody, and is currently undergoing clinical evaluation in a phase I study.

About MediLink

MediLink Therapeutics, founded in 2020, is a clinical stage biotech company dedicated to developing conjugated drugs with global competitiveness. MediLink has developed its proprietary TMALIN® ADC technology platform, enabling the generation of homogeneous ADC with high drug-antibody ratio and improved therapeutic window for the treatment of solid tumors. MediLink aims to provide improved treatment options for global patients and address unmet medical needs. The company is headquartered in Suzhou, China and has established R&D sites in Shanghai, China and Boston, US.